Drug Approval | March 02, 2024
Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg
The product will be launched in March 2024
The product will be launched in March 2024
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
‘Unmask Anemia’ aims to simplify assessment of iron deficiency anemia risk with an easy online self-test based on common signs and symptoms
_Rupak_Singla_256_384.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
_256_384.jpg)
The Vice President also highlighted the importance of preventive healthcare and fitness
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Subscribe To Our Newsletter & Stay Updated
